What to do if the lupus nephritis medicines stop working?

Hi,

Welcome to icliniq.com.

I read your query and can understand your concern.

Lupus nephritis (LN), a kidney disease caused by systemic lupus erythematosus (SLE), a chronic autoimmune disease) that does not respond to standard treatment is considered refractory. This can occur for several reasons, including non-adherence to medication, insufficient treatment, or the accumulation of chronic kidney damage. Although managing refractory LN can be challenging, there are several treatment options available to help control the disease and prevent progression to end-stage kidney disease.

Refractory lupus nephritis is generally defined as a lack of improvement or a worsening of proteinuria (the presence of abnormally high levels of protein in the urine) and/or kidney function despite receiving appropriate treatment with standard immunosuppressive therapy for an adequate period (typically four to six months).

There are several potential causes. The causes are as follows:

1. Non-adherence: Patients may not take their medications as prescribed, either due to personal, psychological, or socioeconomic reasons.

2. Undertreatment: The initial therapy may be insufficient to control disease activity.

3. Accumulated kidney damage: Chronic inflammation over time can impair the kidney’s ability to recover.

4. Genetic predisposition: Some individuals may be more genetically prone to developing treatment-resistant LN.

Several treatment options for refractory lupus nephritis are as follows:

1. Optimizing adherence: Educating the patient about the disease and ensuring they have the support and resources needed to follow their treatment plan consistently.

2. Escalating immunosuppressive therapy: This may include increasing corticosteroid (like Prednisone) doses or switching to a different immunosuppressant, such as Cyclophosphamide or continuing Mycophenolate mofetil.

3. B-cell targeted therapy: Rituximab, a monoclonal antibody that targets B cells, is often used in cases of refractory LN. It may be combined with other agents like Mycophenolate for added effect.

4. Complement inhibition: Eculizumab, a complement system inhibitor, has shown promise, particularly in cases where thrombotic microangiopathy is present.

5. Hematopoietic stem cell transplantation: In very severe and resistant cases, this may be considered, though it carries significant risks and is not commonly used as first- or second-line therapy.

Regular monitoring of kidney function (like serum creatinine and estimated glomerular filtration rate), proteinuria, and other indicators is essential to assess treatment effectiveness and make timely adjustments.

There is currently no cure for lupus nephritis. The goal of treatment is to manage disease activity, minimize symptoms, and prevent long-term damage.

The approach to managing refractory LN must be individualized based on the patient’s overall health, response to prior treatments, and other medical conditions. Long-term management often includes a combination of medications, lifestyle changes, and frequent follow-ups with a nephrologist (kidney specialist) and/or rheumatologist (a medical doctor specializing in diagnosing and treating diseases affecting the joints, muscles, and bones, including arthritis and autoimmune disorders).

Please discuss your sister’s case thoroughly with her physician or nephrologist. Treatment decisions must be personalized, and a detailed in-person evaluation is crucial to determine the best next steps.

I hope this helps.

Kindly revert so I can assist you further.

Thank you.